Golimumab
Golimumab
Golimumab (pronounced goh-lih-MYOO-mab) is a monoclonal antibody used in the treatment of certain autoimmune diseases. It is marketed under the brand name Simponi.
Etymology
The name "Golimumab" is derived from the International Nonproprietary Names (INN), where "goli-" refers to the human source of the antibody, "-m-" indicates its monoclonal nature, and "-ab" is the suffix for all monoclonal antibodies.
Usage
Golimumab is used to treat a variety of autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It works by blocking the action of tumor necrosis factor alpha (TNFα), a substance in the body that causes inflammation.
Administration
Golimumab is administered by subcutaneous injection, typically once a month. It is available in a pre-filled syringe or autoinjector pen.
Side Effects
Common side effects of golimumab include upper respiratory tract infections, high blood pressure, and reactions at the injection site. Serious side effects may include infections such as tuberculosis, cancers, and heart failure.
Related Terms
- Monoclonal antibody
- Autoimmune disease
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Tumor necrosis factor alpha
- Tuberculosis
External links
- Medical encyclopedia article on Golimumab
- Wikipedia's article - Golimumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski